In both S704D-Loxl3 knock-in mice and transplanted tumor models with S704A-LOXL3, LOXL3 was found to be an important counterpart to low-dose Oxaliplatin for the treatment of liver cancer. The gene discussed is LOXL3; the disease is neoplasm.